TISSIUM announced a €60 million financing package to support its commercial and clinical activities and platform expansion. The package combines a completed €30 million Series D2 financing with a €30 million financing facility from the European Investment Bank.
TISSIUM is a medical technology company developing biomorphic programmable polymers for tissue reconstruction. The financing follows a transformational period for the company, including FDA marketing authorization of COAPTIUM CONNECT, its first commercial product.
The company has also entered the U.S. commercial market and continued advancing its pipeline. TISSIUM’s pipeline is focused on unmet needs in atraumatic nerve repair, atraumatic hernia repair, and cardiovascular applications.
The €30 million Series D2 financing was completed at the end of 2025. The round included participation from leading new and existing international investors, including investors in the U.S.
TISSIUM said the Series D2 strengthens its shareholder base and provides capital to support commercial execution, clinical activities, pipeline development, and platform expansion. The funding is expected to help the company build on its transition into a commercial-stage medtech business.
The company also secured a financing facility of up to €30 million from the European Investment Bank. The facility aligns with the objectives of InvestEU, which supports research, innovation, and the development of transformative healthcare technologies across Europe.
The EIB facility is available in three €10 million tranches tied to commercial, clinical, and financing milestones. The facility includes a mix of dilutive and venture debt financing, and TISSIUM expects to draw the first €10 million tranche before the end of June 2026.
TISSIUM said the combined financing provides strategic flexibility as it rolls out COAPTIUM CONNECT commercially in the U.S. The company also plans to advance multiple clinical programs across surgical applications while continuing to expand its proprietary biomorphic polymer platform.
KEY QUOTE:
“This financing marks an important milestone in TISSIUM’s evolution. Following the FDA marketing authorization of COAPTIUM® CONNECT, we are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform. The support of both leading international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients. This financing provides the capital and strategic flexibility required to accelerate commercial execution while continuing to invest in the future growth of our platform.”
Christophe Bancel, CEO and Co-Founder of TISSIUM
